Study Characteristics | |||||||||
---|---|---|---|---|---|---|---|---|---|
Trial ID | Country | Study Design | Funded By Industry | N | Treatment Arms | Number of injections | OA Severity (KL) | Visit closest to 26Â weeks (weeks) | |
 |  |  |  |  | Treatment | Control |  |  |  |
Altman, 2004 | USA, Canada, Sweden | Double-blinded RCT | Yes | 346 | Durolane | Saline | 1 | 2,3,4 | 26 |
Altman, 2009 | USA | Double-blinded RCT | Yes | 588 | Euflexxa | Saline | 3 | 2,3 | 26 |
Arden, 2014 | Sweden, German, UK | Double-blinded RCT | Yes | 218 | Durolane | Saline | 1 | 2,3 | 6 |
Brandt, 2001 | USA | Double-blinded RCT | Yes | 226 | Orthovisc | Saline | 3 | NR | 27 |
Chevalier, 2010 | UK, France, Czech Republic, Germany, Belgium, Netherlands | Double-blinded RCT | Yes | 253 | Synvisc | Saline | 1 | 2,3,4 | 26 |
Creamer, 1994 | UK | Single-blinded RCT | Yes | 12 | Hyalgan | Saline | 5 | 2,3,4 | 5 |
Day, 2004 | Australia | Double-blinded RCT | Yes | 240 | Artzal | Saline | 5 | NR | 18 |
DeCaria, 2012 | Canada | Double-blinded RCT | Yes | 30 | Low MW HA | Sham HA | 3 | NR | 26 |
Diracoglu, 2009 | Turkey | Double-blinded RCT | No | 63 | Synvisc | Saline | 3 | 2,3 | 4 |
Dixon, 1988 | UK | Double-blinded RCT | Yes | 63 | Hyalgan | 1/100 Hyalgan | 1–11 | NR | 25 |
Henderson, 1994 | UK | Double-blinded RCT | No | 91 | Hyalgan | Saline | 5 | 2,3,4 | 5 |
Huang, 2011 | Taiwan | Double-blinded RCT | Yes | 200 | Hyalgan | Saline | 5 | 2,3 | 25 |
Huskisson, 1999 | UK | Single-blinded RCT | No | 100 | Hyalgan | Saline | 5 | 2,3 | 26 |
Jorgensen, 2010 | Denmark | Double-blinded RCT | No | 337 | Hyalgan | Saline | 5 | NR | 26 |
Karlsson, 2002 | Sweden | Double-blinded RCT | Yes | 246 | Synvisc | Saline | 3 | NR | 26 |
Kotevoglu, 2006 | Turkey | Double-blinded RCT | No | 78 | Synvisc | Saline | 3 | 2,3,4 | 27 |
Lohmander, 1996 | Denmark, Finland, Norway, Sweden | Double-blinded RCT | Yes | 240 | Artzal | Saline | 5 | NR | 20 |
Lundsgaard, 2008 | UK, Netherlands | Double-blinded RCT | No | 308 | Hyalgan | Saline | 4 | 1,2,3,4 | 26 |
Navarro-Sarabia 2011 | Spain | Double-blinded RCT | Yes | 306 | Adant | Saline | 5 | 2,3 | 28 |
Neustadt, 2005 | USA, Canada | Double-blinded RCT | Yes | 229 | Orthovisc | Arthrocentesis | 4 | 1,2,3 | 22 |
Petrella, 2006 | Canada | Double-blinded RCT | Yes | 106 | HA sodium salt | Saline | 3 | 1,2,3 | 12 |
Petrella, 2008 | Canada | Double-blinded RCT | No | 200 | Synvisc | Saline | 3 | 1,2 | 16 |
Pham, 2004 | France | Double-blinded RCT | No | 301 | NRD101 HA | Saline | 3 | 1,2,3,4 | 52 |
Puhl, 1993 | Germany | Double-blinded RCT | Yes | 209 | Artzal | 1/100 ARTZ | 5 | NR | 14 |
Scale, 1994 | USA | Double-blinded RCT | Yes | 80 | Synvisc | Saline | 2, 3 | 2,3,4 | 12 |
Sezgin, 2005 | Turkey | Single-blinded RCT | No | 41 | Orthovisc | Saline | 3 | 2,3 | 4 |
Strand, 2012 | Japan | Double-blinded RCT | Yes | 379 | Gel-ONE | Saline | 1 | 1,2,3 | 13 |
Tamir, 2001 | Israel | Single-blinded RCT | No | 49 | BioHY | Saline | 5 | 2,3,4 | 20 |
van der Weegen, 2015 | Netherlands | Double-blinded RCT | Yes | 196 | Fermathron plus | Saline | 3 | 1,2,3 | 26 |
Wobig, 1998 | Germany | Double-blinded RCT | Yes | 110 | Synvisc | Saline | 3 | 1,2,3 | 26 |